Lexeo Therapeutics Inc (LXEO) - News Archive

: Lexeo Therapeutics, a clinical-stage genetic medicine company, has announced positive interim results from its Phase 1/2 clinical trial for LX2006, a gene therapy targeting Friedreich ataxia (FA) cardiomyopathy. The i...

In the world of pharmaceutical sciences, the performance of biotech companies and the impact of clinical trial results play a crucial role in shaping investor sentiment. This article focuses on Lexeo Therapeutics Inc an...

Lexeo Therapeutics Revolutionizes the Treatment of Cardiomyopathies with Promising Clinical Data and Regulatory MilestonesLexeo Therapeutics, a leading gene therapy company, made significant strides in the development o...

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyLexeo Therapeutics, a clinical stage genetic medicine company focuse...

Lexeo Therapeutics, a leading name in genetic medicine, has recently announced an arrangement empowering them to fast-track the development of their novel treatment for a rare disorder, Friedreich Ataxia Cardiomyopathy...

Lexeo Therapeutics, a leading biotechnology company focused on developing novel gene therapy treatments, has announced the successful closing of an oversubscribed $95.0 million equity financing round. The funding, which...

Lexeo Therapeutics Secures $95 Million in Equity Financing, Extends Runway to 2027Lexeo Therapeutics announced an oversubscribed $95.0 million equity financing, extending their financial runway into 2027 with a private...

Lexeo Therapeutics, a pioneering biotech company, has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for their revolutionary gene therapy candidate, LX2020...